WCI

RI Related News

게시글 목록
No TItle Name Date Hit
755 Aktis Oncology Announces Actinium-225 Supply Agreements with Leading Isotope Producers WCI Secretariat 2022/09/08 879
754 ITM Acquires a New Platform for the Development of Next-Generation Theranostics WCI Secretariat 2022/09/08 927
753 POINT Biopharma to Publish Abstract at ESMO Congress 2022 Containing Efficacy & Safety Data from Lead-In Cohort of Phase 3 SPLASH Trial WCI Secretariat 2022/09/08 869
752 NRG and Curium Sign Multi-Year Isotope Production Contract WCI Secretariat 2022/09/08 873
751 Fusion Pharmaceuticals Announces Second Quarter 2022 Financial Results And Clinical Program Updates WCI Secretariat 2022/09/08 833
750 Imaging trial with SAR-Bombesin in prostate cancer opens for recruitment in Australia WCI Secretariat 2022/09/08 832
749 Clarity and Evergreen expand Targeted Copper Theranostics manufacturing WCI Secretariat 2022/09/08 862
748 Dutch regulator receives licence application for PALLAS reactor WCI Secretariat 2022/09/08 898
747 Radiopharm Enters into Strategic Collaboration with LANTHEUS and Assumes PD-L1 Licensing Agreement from NANOMAB WCI Secretariat 2022/09/08 845
746 New CRP: Understanding the importance of convective rain events and tracing their impact on the catchment with isotopes (F31007) WCI Secretariat 2022/09/08 870
745 Ablaze Pharma Aligned The Strategic Agreement With Wenjiang District Government of Chengdu to Build-up the Innovative R&D and Manufacturing Center for Targeted Radiopharmaceutical Therapies WCI Secretariat 2022/09/08 875
744 SHINE moving from R&D into the commercial stage for cancer therapy product, exec says WCI Secretariat 2022/09/08 868
743 SHINE Submits Drug Master File for n.c.a. Lu-177 WCI Secretariat 2022/09/08 888
742 Zero-Spin Silicon Project Completes Construction of Stage 3 Pilot Demonstration Facility WCI Secretariat 2022/08/04 908
741 ITM Signs Clinical Supply Agreement with Y-mAbs for n.c.a. Lutetium-177 (copy 1) WCI Secretariat 2022/08/04 641
First Prev 1 2 3 4 5 6 7 8 9 10 End (55 Page)

비밀글입니다!

글작성시 입력했던 비밀번호를 입력해주세요.